Skip to main content
Contact Us
Subscribe
E-Edition
63°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
2025 Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ultragenyx Pharmaceu
(NQ:
RARE
)
55.10
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Ultragenyx Pharmaceu
< Previous
1
2
3
4
5
Next >
Breaking Down Ultragenyx Pharmaceutical: 10 Analysts Share Their Views
September 20, 2024
Via
Benzinga
Novartis And Viatris Sued Over Unlawful Use Of HeLa Cells Used For Cancer Treatment Drugs
August 06, 2024
Henrietta Lacks' family sues Novartis and Viatris for profiting from her HeLa cells without consent. The lawsuit seeks profits and aims to prevent further unauthorized use of the cells.
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
3 Genomics Stocks That May Transform Personalized Medicine
August 06, 2024
These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry.
Via
InvestorPlace
Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst
July 22, 2024
Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety...
Via
Benzinga
Unveiling 14 Analyst Insights On Ultragenyx Pharmaceutical
July 22, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Ultragenyx Pharmaceutical Through Analyst Insights
May 31, 2024
Via
Benzinga
Forecasting The Future: 11 Analyst Projections For Ultragenyx Pharmaceutical
April 22, 2024
Via
Benzinga
Expert Outlook: Ultragenyx Pharmaceutical Through The Eyes Of 9 Analysts
April 05, 2024
Via
Benzinga
Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong
July 22, 2024
Biogen previously decided against opting into Ionis' Angelman program.
Via
Investor's Business Daily
7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
June 17, 2024
With biotech stocks enjoying a permanently relevant narrative, investors should focus on these compelling opportunities.
Via
InvestorPlace
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
June 14, 2024
Via
Benzinga
Analyst Scoreboard: 8 Ratings For Ultragenyx Pharmaceutical
March 18, 2024
Via
Benzinga
Recap: Ultragenyx Pharmaceutical Q4 Earnings
February 15, 2024
Via
Benzinga
The Latest Analyst Ratings For Ultragenyx Pharmaceutical
February 15, 2024
Via
Benzinga
Dave & Buster's Posts Downbeat Results, Joins J.Jill And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
June 13, 2024
Via
Benzinga
This United Airlines Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
June 06, 2024
Via
Benzinga
Ultragenyx Faces Lawsuit Over Alleged Unjust Use of Henrietta Lacks' Cells
May 22, 2024
The estate of Henrietta Lacks can proceed with a lawsuit against Ultragenyx Pharmaceutical over the use of HeLa cells taken without her consent in the 1950s. A Maryland federal court ruled against...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
RARE Stock Earnings: Ultragenyx Pharmaceutical Misses EPS, Misses Revenue for Q1 2024
May 02, 2024
RARE stock results show that Ultragenyx Pharmaceutical missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
S&P 500 Down Over 1%; US Retail Sales Increase 0.7% In March
April 15, 2024
U.S. stocks turned lower toward the end of trading, with the S&P 500 falling more than 1% on Monday. The Dow traded down 0.64% to 37,741.18 while the NASDAQ fell 1.68% to 15,902.96. The S&P 500 also...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Earnings Scheduled For February 15, 2024
February 15, 2024
Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.
Via
Benzinga
Preview: Ultragenyx Pharmaceutical's Earnings
February 14, 2024
Via
Benzinga
4 Analysts Have This To Say About Ultragenyx Pharmaceutical
January 19, 2024
Via
Benzinga
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 15, 2024
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic...
Via
Benzinga
Crude Oil Down 1%; Charles Schwab Sales Top Estimates
April 15, 2024
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday. The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&P...
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Expert Ratings for Ultragenyx Pharmaceutical
December 08, 2023
Via
Benzinga
Analyst Ratings for Ultragenyx Pharmaceutical
November 03, 2023
Via
Benzinga
Rare Disease-Focused-Ultragenyx Pharmaceutical Stock Falls On Serious Adverse Events In Eaarly Genetic Disorder Study
April 15, 2024
New data from Phase 1/2 study of GTX-102 for Angelman syndrome shows rapid and sustained improvement in patients, exceeding natural history data.
Via
Benzinga
Marinus Pharmaceuticals, Neumora Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
April 15, 2024
U.S. stock futures were higher this morning, with the Dow futures gaining over 200 points on Monday.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Ultragenyx Pharm Stock Earns IBD Stock Upgrade With RS Rating Jump To 83
January 18, 2024
On Thursday, Ultragenyx Pharm stock just cleared that 80 or higher RS Rating benchmark with an upgrade from 75 to 83.
Via
Investor's Business Daily
Ultragenyx Pharm Stock Hits 80-Plus Relative Strength Rating Benchmark
December 28, 2023
On Thursday, Ultragenyx Pharm stock received a positive adjustment to its Relative Strength (RS) Rating, from 77 to 81.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.